期刊文献+

3β-羟基雄甾-4-烯-6,17-二酮的合成 被引量:2

Synthesis of 3β-Hydroxyandrost-4-en-6,17-dione
下载PDF
导出
摘要 去氢表雄酮醋酸酯经过氧甲酸环氧化、高碘酸开环、IBX氧化、脱水和碱性水解等5步反应,以55%的总收率合成得到了非雄性激素芳香化酶抑制剂3β-羟基雄甾-4-烯-6,17-二酮。在环氧化反应中,利用价廉、易制备的过氧甲酸以几乎定量的收率得到了环氧化合物。使用IBX氧化邻二醇,以98.5%的收率得到氧化产物,避免了使用处理困难并且污染环境的铬试剂。 3β-Hydroxyandrost-4-en-6, 17-dione (3-OHAT), a non-androgenic aromatase inhibitor, was synthesized via a new process. With dehydroepiandrosterone acetate as starting material, the synthetic procedure included five steps: epoxidation of C=C bond with performic acid, ring opening of the epoxide with periodic acid, oxidation of 6-hydroxy by IBX, elimination of H2O and hydrolysis of the ester. The total yield was up to 55 %. The use of performie acid, an affordable and easily prepared reagent, in epoxidation led to quantitatively the target epoxide. The oxidation of the 1,2-diol by IBX provided the oxidative product with a high yield of 98.5% , moreover, the introduction of IBX avoided the use of chromic reagent, which leads to the tedious work-up for the product purification and environmental pollution.
出处 《应用化学》 CAS CSCD 北大核心 2006年第12期1422-1424,共3页 Chinese Journal of Applied Chemistry
基金 上海市科委基础研究重点项目(04JC14032)
关键词 3β-羟基雄甾烯二酮 IBX 合成 3β-Hydroxyandrost-en-dione, IBX, synthesis
  • 相关文献

参考文献11

  • 1Numazawa M,Tsuji M,Mutsumi A.J Steroid Biochem[J],1987,28:337
  • 2Lábler L,Sláma K,orn F.Coll Czech Chem Commun[J],1968,33:2 226
  • 3Deive N,Rodriguez J,Jimenez C.J Med Chem[J],2001,44:2 612
  • 4Frigerio M,Santagostino M,Sputore S.J Org Chem[J],1999,64:4
  • 5Fieser L F,Rajagopalan S.J Am Chem Soc[J],1949,71:3 938
  • 6HUANGMing-Long(黄鸣龙) HANGuang-Dian(韩广甸) ZHOUWei-Shan(周维善).化学学报,1963,29:99-99.
  • 7Flaih N,Hanson J R.J Chem Soc Perkin Trans 1[J],1990:2 667
  • 8Fieser M,Fieser L F.Reagents Organic Synthesis[J],1975,5:818
  • 9Frigerio M,Santagostino M.Tetrahedron Lett[J],1994,35:8 019
  • 10Lardon A,Reichstein T.Helv Chim Acta[J],1958,41:904

同被引文献37

  • 1Numazawa M,Tsuji M,Mutsumi A.J Steroid Biochem[J],1987,28:337.
  • 2Lbler L,Slma K,om F.Coll Czech Chem Commun[J],1968,33(2):226.
  • 3Deive N,Rodriguez J,Jinenez C.J Med Chem[J],2001,44(2):612.
  • 4Corey E J,Suggs W.Tetrahedron Lett[J],1975,31:2647.
  • 5Nagia A,Anthony A.Synth Commun[J],1996,26:225.
  • 6Hunter A C,Priest S M.Steroids[J],2006,71:30.
  • 7Rasmusson G H, Reynolds G F, Steinberg N G, et al. Azasteroids: structure - activity relationship for inhibition of 5 - reductase and of androgen acceptor binding[ J ]. Journal of Medicinal Chemistry, 1986,29 (11 ) : 2298 -2315.
  • 8Andriole G L, Kirby R. Safety and tolerability of the dual 5a - reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia[ J]. European Urology, 2003, 44(1) : 82 - 88.
  • 9Huang L H, Zheng Y F, Lu Y Z, et al. Synthesis and biological evaluation of novel steroidal[ 17,16 - d] [ 1,2,4] triazolo[ 1, 5 - a] pyrimidines[ J]. Steroids, 2012, 77 : 710 - 715.
  • 10Robertson J F, Come S E, Jones S E,et al. Endocrine treatment options for advanced breast cancer: the role of fulvestrant[ J]. European Journal of Cancer, 2005, 41 (3) : 346 -356.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部